Dry Powder Inhalation Products

Micro Tooling Considerations
May 28, 2018
Cutting Edge MICRO Technology In The Medical And Pharma Fields
June 15, 2018

Dry Powder Inhalation Products

3/23/17 www.Dose-One.com

The DoseOne™ dry powder inhaler is capsule based with a new needle technology that can pierce the capsule with no particles detaching from the capsule and the powder is delivered directly through the needle. The result is a disposable three piece molded device storing the capsule, which can be actuated and inhaled by the patient in one step. No dose counter is required and a window in the device gives the patient visual confirmation of an empty capsule after inhalation. It was designed to be simple to use, disposable and cost effective to manufacture.

We are currently looking to partner with a pharmaceutical company to bring this device to market. It has been prototyped, tested, benchmarked and is ready for pilot production. DoseOne™ is simple, inexpensive and can be brought to market quickly as it is already designed, injection molded and geared for fast iteration for the incorporation of minor modifications for a multitude of drug/excipient molecule sizes.

Monash University wrote an article about DPIs:

D4 researchers are exploring opportunities where drug delivery to the airways can improve health outcomes for certain patient populations. The lungs present a large surface area with an extensive blood supply and thin epithelial cells. This can facilitate absorption of some compounds so that medication reaches the bloodstream without the need for an injection. In certain disease states, it is beneficial to deliver medicine to the site of action. D4 researchers are therefore investigating the role of inhaled antibiotics for respiratory infections.

Researchers are working to develop a novel aerosol delivery system for oxytocin that can be inhaled by patients immediately after childbirth, using a simple, disposable device. This approach will increase access to potentially life-saving treatment in resource-poor settings—where a large number of women give birth outside medical facilities or in understaffed and ill-equipped clinics with limited or no refrigeration facilities.

Pulmonary immunization has gained increased recognition as a means of triggering both a mucosal and systemic immune response without the use of needles. The appropriate formulation of antigens in a dry, solid state can result in improved stability, thereby removing cold-chain storage complications associated with conventional liquid-based vaccines.

Delivery of the antibiotic via inhalation, as compared to intravenous administration, has the potential to achieve higher concentrations within the respiratory tract while minimizing systemic exposure. These effects combined are likely to improve clinical efficacy and reduce adverse effects.

If you are interested in learning more about our DPI, please email [email protected]

We are currently looking to partner with a pharmaceutical company to bring this device to market. It has been prototyped, tested, benchmarked and is ready for pilot production. DoseOne™ is simple, inexpensive and can be brought to market quickly as it is already designed, injection molded and geared for fast iteration for the incorporation of minor modifications for a multitude of drug/excipient molecule sizes.

Monash University wrote an article about DPIs:

D4 researchers are exploring opportunities where drug delivery to the airways can improve health outcomes for certain patient populations. The lungs present a large surface area with an extensive blood supply and thin epithelial cells. This can facilitate absorption of some compounds so that medication reaches the bloodstream without the need for an injection. In certain disease states, it is beneficial to deliver medicine to the site of action. D4 researchers are therefore investigating the role of inhaled antibiotics for respiratory infections.

Researchers are working to develop a novel aerosol delivery system for oxytocin that can be inhaled by patients immediately after childbirth, using a simple, disposable device. This approach will increase access to potentially life-saving treatment in resource-poor settings—where a large number of women give birth outside medical facilities or in understaffed and ill-equipped clinics with limited or no refrigeration facilities.

Pulmonary immunization has gained increased recognition as a means of triggering both a mucosal and systemic immune response without the use of needles. The appropriate formulation of antigens in a dry, solid state can result in improved stability, thereby removing cold-chain storage complications associated with conventional liquid-based vaccines.

Delivery of the antibiotic via inhalation, as compared to intravenous administration, has the potential to achieve higher concentrations within the respiratory tract while minimizing systemic exposure. These effects combined are likely to improve clinical efficacy and reduce adverse effects.

If you are interested in learning more about our DPI, please email [email protected]

✉ Contact Us Now!
close slider